Castle Biosciences Quarterly Balance Sheet
NASDAQ: CSTLHealth CareMedical SpecialitiesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Castle Biosciences financial position
As of Jun 30, 2026, Castle Biosciences reported total assets of $561.2 million, up 3.0% from a year earlier against total liabilities of $91.1 million. Shareholders' equity stood at $470.0 million, or 83.8% of assets. The company held $62.1 million in cash and equivalents against $10.1 million of debt, a net cash position of $52.0 million.
The current ratio (current assets divided by current liabilities) was 6.04, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.02.
Summary generated from market data by MetaCap's automated system. Methodology
Castle Biosciences balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 62.12M | 63.76M | 116.73M | 85.56M | 82.23M | 89.69M | 119.71M | 94.96M | 85.57M | 82.95M | 98.84M | 91.22M |
| Short-Term Investments | 204.69M | 197.92M | 182.78M | 201.99M | 193.70M | 185.46M | 173.42M | 184.83M | 174.12M | 156.26M | 144.26M | 138.53M |
| Receivables | 48.34M | 42.26M | 43.38M | 49.48M | 52.31M | 56.35M | 51.22M | 50.26M | 45.99M | 42.70M | 38.30M | 37.00M |
| Inventory | 10.58M | 10.46M | 10.25M | 8.65M | 8.37M | 6.85M | 8.13M | 6.57M | 8.01M | 7.64M | 7.94M | 5.77M |
| Total Current Assets | 341.10M | 328.90M | 361.10M | 357.57M | 348.67M | 349.39M | 360.15M | 344.77M | 320.40M | 295.78M | 295.63M | 279.62M |
| Property, Plant & Equipment | 104.68M | 100.93M | 97.44M | 84.89M | 74.06M | 55.42M | 51.12M | 44.38M | 38.64M | 32.90M | 25.43M | 22.27M |
| Goodwill | 10.70M | 10.70M | 10.70M | 10.70M | 10.70M | 10.70M | 10.70M | 10.70M | 10.70M | 10.70M | 10.70M | 10.70M |
| Intangible Assets | 84.40M | 86.66M | 88.88M | 91.16M | 93.43M | 67.21M | 95.54M | 99.88M | 102.15M | 104.40M | 106.64M | 108.92M |
| Long-Term Investments | — | — | — | — | — | 5.57M | 0 | — | — | — | — | — |
| Total Assets | 561.18M | 547.80M | 578.56M | 562.79M | 544.73M | 501.71M | 531.24M | 514.57M | 487.31M | 458.51M | 453.34M | 436.02M |
| Accounts Payable | 9.67M | 15.04M | 18.71M | 12.21M | 13.18M | 8.50M | 6.90M | 6.81M | 9.54M | 9.32M | 10.27M | 6.93M |
| Short-Term Debt | 2.92M | 1.67M | 417.00K | 0 | 1.94M | 1.11M | 278.00K | 0 | 0 | 0 | 0 | — |
| Total Current Liabilities | 56.51M | 48.76M | 68.68M | 55.31M | 50.89M | 37.27M | 49.39M | 44.30M | 39.45M | 31.96M | 47.67M | 36.32M |
| Long-Term Debt | 7.16M | 8.40M | 9.64M | 10.05M | 8.10M | 8.92M | 9.74M | 10.02M | 10.01M | 10.00M | 0 | — |
| Total Liabilities | 91.15M | 86.39M | 107.68M | 95.74M | 89.35M | 61.41M | 75.40M | 73.51M | 63.42M | 56.05M | 62.07M | 50.24M |
| Shareholders' Equity | 470.03M | 461.42M | 470.87M | 467.05M | 455.38M | 440.31M | 455.83M | 441.06M | 423.89M | 402.46M | 391.27M | 385.78M |
| Retained Earnings | -240.87M | -238.81M | -224.28M | -221.95M | -221.45M | -225.97M | -200.13M | -209.72M | -211.99M | -220.91M | -218.37M | -215.79M |
| Total Debt | 10.07M | 10.07M | 10.06M | 10.05M | 10.04M | 10.03M | 10.02M | 10.02M | 10.01M | 10.00M | 0 | — |
| Net Cash (Debt) | 256.73M | 251.62M | 289.45M | 277.49M | 265.89M | 265.12M | 283.11M | 269.77M | 249.68M | 229.21M | 243.10M | 229.75M |
| Shares Outstanding | 30.51M | 30.30M | 29.69M | 29.16M | 28.98M | 28.84M | 28.48M | 27.98M | 27.71M | 27.59M | 27.41M | 26.89M |
This table shows 12 quarterly periods of Castle Biosciences's balance sheet, from Q2 2026 back to Q3 2023, across 20 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow CSTL's reporting calendar. What is a balance sheet?